Patents by Inventor Sybil M. G. Williams

Sybil M. G. Williams has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-TIGIT antibodies
    Patent number: 11958902
    Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: April 16, 2024
    Assignee: Merck Sharp & Dohme LLC
    Inventors: Sybil M. G. Williams, Wolfgang Seghezzi, Laurence Fayadat-Dilman, Linda Liang, Veronica Juan
  • METHODS FOR TREATING CANCER OR INFECTION USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY, AN ANTI-CTLA4 ANTIBODY, AND AN ANTI-TIGIT ANTIBODY
    Publication number: 20230092707
    Abstract: Provided herein are methods of treating a cancer, an infectious disease or infection, which comprise administering to a subject in need thereof a combination of agents: (a) an anti-human PD-1 antibody or antigen binding fragment thereof; (b) an anti-human CTLA4 antibody or antigen binding fragment thereof; and (c) an anti-human TIGIT antibody or antigen binding fragment thereof. Also provided are therapeutic combinations for use, pharmaceutical compositions and kits containing such agents for the treatment of a cancer, an infectious disease, or an infection.
    Type: Application
    Filed: March 4, 2021
    Publication date: March 23, 2023
    Applicant: MERCK SHARP & DOHME LLC
    Inventors: Rachel A. Altura, Mingmei Cai, Scott J. Diede, Jane Anne Healy, Blanca Homet Moreno, Nageatte Ibrahim, Sybil M.G. Williams
  • BIOMARKERS FOR ANTI-TIGIT ANTIBODY TREATMENT
    Publication number: 20220340660
    Abstract: Novel methods for selecting a patient with a cancer for treatment with a TIGIT antagonist are disclosed. The methods employ various biomarkers, including CD45, CD3?, CD11b, Foxp3, IFN-?, Cxcl11, Cxcl10, TNF-?, IL-23, MHC class II, CD80, CD86, and CD40.
    Type: Application
    Filed: October 1, 2019
    Publication date: October 27, 2022
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Sybil M.G. Williams, Jin-Hwan Han, Drake Maurice LaFace, Elaine Pinheiro, Wolfgang Seghezzi
  • DOSING REGIMEN OF ANTI-TIGIT ANTIBODY FOR TREATMENT OF CANCER
    Publication number: 20210403557
    Abstract: The present invention relates to dosing regimens of an anti-TIGIT antibody useful for the treatment of cancer. In particular, the invention relates to the dosing regimen in a combination therapy which comprises administering an antibody of a Programmed Death 1 protein (PD-1) or Programmed Death Ligand 1 (PD-L1) and an anti-TIGIT antibody.
    Type: Application
    Filed: November 4, 2019
    Publication date: December 30, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Mingmei Cai, Elliot K. Chartash, Jane Anne Healy, Mallika Lala, Tommy Ruosi Li, Kapil Mayawala, Raluca Andreia Predoiu, Sybil M.G. Williams, Zhen Zeng
  • ANTI-TIGIT ANTIBODIES
    Publication number: 20210017276
    Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: July 27, 2020
    Publication date: January 21, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Sybil M.G. Williams, Wolfgang Seghezzi, Laurence Fayadat-Dilman, Linda Liang, Veronica Juan
  • Anti-TIGIT antibodies
    Patent number: 10766957
    Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Grant
    Filed: August 9, 2016
    Date of Patent: September 8, 2020
    Assignee: MERCK SHARP & DOHME CORP
    Inventors: Sybil M. G. Williams, Wolfgang Seghezzi, Laurence Fayadat-Dilman, Linda Liang, Veronica Juan
  • ANTI-TIGIT ANTIBODIES
    Publication number: 20200270346
    Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: May 15, 2020
    Publication date: August 27, 2020
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Sybil M. G. Williams, Drake LaFace, Laurence Fayadat-Dilman, Gopalan Raghunathan, Linda Liang, Wolfgang Seghezzi
  • Anti-TIGIT antibodies
    Patent number: 10618958
    Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Grant
    Filed: November 20, 2017
    Date of Patent: April 14, 2020
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Sybil M. G. Williams, Drake LaFace, Laurence Fayadat-Dilman, Gopalan Raghunathan, Linda Liang, Wolfgang Seghezzi
  • ANTI-TIGIT ANTIBODIES
    Publication number: 20180371083
    Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: August 9, 2016
    Publication date: December 27, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Sybil M.G. Williams, Wolfgang Seghezzi, Laurence Fayadat-Dilman, Linda Liang, Veronica Juan
  • ANTI-TIGIT ANTIBODIES
    Publication number: 20180066055
    Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: November 20, 2017
    Publication date: March 8, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Sybil M. G. Williams, Drake LaFace, Laurence Fayadat-Dilman, Gopalan Raghunathan, Linda Liang, Wolfgang Seghezzi
  • ANTI-TIGIT ANTIBODIES
    Publication number: 20170198042
    Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: March 22, 2017
    Publication date: July 13, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Sybil M. G. Williams, Drake LaFace, Laurence Fayadat-Dilman, Gopalan Raghunathan, Linda Liang, Wolfgang Seghezzi
  • ANTI-TIGIT ANTIBODIES
    Publication number: 20160355589
    Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: August 17, 2015
    Publication date: December 8, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Sybil M. G. Williams, Drake LaFace, Laurence Fayadat-Dilman, Gopalan Raghunathan, Linda Liang, Wolfgang Seghezzi